Print this page
-
Sequential Combined TAS-102 and Oxaliplatin Alternating with TAS-102 and Irinotecan (Sequential TASOXIRI) with Bevacizumab for Late-Line Metastatic Colorectal Cancer.
Protocol: 072303Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Colon -
A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy Delivery.
Protocol: 072201Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Colon -
Choices About Genetic Testing And Learning Your Risk with Smart Technology (CATALYST)
Protocol: 132307Principal Investigator:
- Anita Kinney PhD,RN (Rutgers University)
Applicable Disease Sites: Pancreas
Other Female Genital
Prostate
Colon
Ovary
Breast -
Practices, knowledge and beliefs of colorectal cancer patients and their providers prescription practices regarding anemia and oral iron supplementation
Protocol: 132003Principal Investigator:
- Carolyn Heckman Ph.D. (Rutgers University)
Applicable Disease Sites: Rectum
Colon -
A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations.
Protocol: 052216Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Anus
Small Intestine
Colon
Esophagus
Stomach
Rectum
Other Digestive Organ
Pancreas -
A Phase 2 Study of CTX-009 in Adult Patients with Metastatic Colorectal Cancer who have received Two or Three Prior Systemic Chemotherapy Regimens.
Protocol: 072301Principal Investigator:
- Patrick Boland (Rutgers University)
Applicable Disease Sites: Colon
- 1
- 2